Please assess the completion status of the following clinical trial:

Trial Title: Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with T1D for at least 6 months at Screening.~* current usage of daily insulin treatment.~Exclusion Criteria:~* pregnant or nursing~* renal insufficiency~* hepatic synthetic insufficiency~* aspartate or alanine aminotransferase \> 3 times the upper limit of normal~* hematocrit less than or equal to 30%~* use of \> 2.0 U/kg total insulin dose per day~* inadequate venous access~* current seizure disorder~* history of pheochromocytoma or disorder with increased risk of pheochromocytoma~* history of insulinoma~* history of glycogen storage disease.~* active use of alcohol or drugs of abuse~* administration of glucagon within 14 days of the first treatment visit~* participation in other studies involving an investigational drug or device within 30 days

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- G-Pen (glucagon injection) 0.5 mg (Type: EXPERIMENTAL): A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
- G-Pen (glucagon injection) 1.0 mg (Type: EXPERIMENTAL): A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).